Published in Int J Cancer on January 24, 2012
Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer (2014) 1.83
HLA-binding properties of tumor neoepitopes in humans. Cancer Immunol Res (2014) 1.37
Immunological monitoring of anticancer vaccines in clinical trials. Oncoimmunology (2013) 0.95
Clinical evaluation of therapeutic cancer vaccines. Hum Vaccin Immunother (2013) 0.93
Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci (2015) 0.90
Challenges in the development of an autologous heat shock protein based anti-tumor vaccine. Hum Vaccin Immunother (2012) 0.88
Placenta-derived gp96 as a multivalent prophylactic cancer vaccine. Sci Rep (2013) 0.83
The role of glycoprotein 96 in the persistent inflammation of rheumatoid arthritis. Arch Biochem Biophys (2012) 0.79
Induction of regulatory T cells by high-dose gp96 suppresses murine liver immune hyperactivation. PLoS One (2013) 0.79
Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice. Blood (2014) 0.78
Endoplasmic reticulum chaperones and their roles in the immunogenicity of cancer vaccines. Front Oncol (2015) 0.77
Dendritic-tumor fusion cells derived heat shock protein70-peptide complex has enhanced immunogenicity. PLoS One (2015) 0.76
Interaction of Toll-Like Receptors with the Molecular Chaperone Gp96 Is Essential for Its Activation of Cytotoxic T Lymphocyte Response. PLoS One (2016) 0.75
Gastric cancer-derived heat shock protein-gp96 peptide complex enhances dendritic cell activation. World J Gastroenterol (2017) 0.75
Antibodies against MICA antigens and kidney-transplant rejection. N Engl J Med (2007) 5.31
Inhibition of allogeneic T cell proliferation by indoleamine 2,3-dioxygenase-expressing dendritic cells: mediation of suppression by tryptophan metabolites. J Exp Med (2002) 3.75
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation (2013) 2.55
C3 polymorphisms and allograft outcome in renal transplantation. N Engl J Med (2009) 2.29
Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer (2009) 2.26
Critical evaluation of the amino acid triplet-epitope matching concept in cadaver kidney transplantation. Transplantation (2004) 2.13
IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol Immunother (2008) 1.88
H-Y as a minor histocompatibility antigen in kidney transplantation: a retrospective cohort study. Lancet (2008) 1.85
Regulation of human auto- and alloreactive T cells by indoleamine 2,3-dioxygenase (IDO)-producing dendritic cells: too much ado about IDO? Blood (2004) 1.83
Serial peripheral blood perforin and granzyme B gene expression measurements for prediction of acute rejection in kidney graft recipients. Am J Transplant (2003) 1.76
The effect of donor gender on graft survival. J Am Soc Nephrol (2002) 1.72
No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation (2011) 1.67
Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun (2009) 1.65
Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun (2010) 1.62
Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation (2008) 1.55
Living kidney donor follow-up: state-of-the-art and future directions, conference summary and recommendations. Am J Transplant (2011) 1.51
Malignancy in renal transplantation. J Am Soc Nephrol (2004) 1.50
Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood (2007) 1.48
Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int (2012) 1.47
Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation (2009) 1.47
Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo. Transpl Int (2005) 1.43
Ex vivo perfusion with mitomycin C containing solution prolongs heart graft survival in rats. Transplantation (2006) 1.41
Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation (2013) 1.36
A cell line model for the differentiation of human dendritic cells. Biochem Biophys Res Commun (2005) 1.28
Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood (2004) 1.26
Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells. J Cell Biochem (2008) 1.20
Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma. Exp Hematol (2006) 1.14
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology (2008) 1.14
The Risk of Transplant Failure With HLA Mismatch in First Adult Kidney Allografts From Deceased Donors. Transplantation (2016) 1.13
Disassociation between risk of graft loss and risk of non-Hodgkin lymphoma with induction agents in renal transplant recipients. Transplantation (2006) 1.11
Cytokine expression during early and late phase of acute Puumala hantavirus infection. BMC Immunol (2011) 1.09
The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol (2006) 1.07
Kidney graft failure and presensitization against HLA class I and class II antigens. Transplantation (2002) 1.04
Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol (2008) 1.02
Effect on kidney graft survival of reducing or discontinuing maintenance immunosuppression after the first year posttransplant. Transplantation (2008) 1.00
Inosine monophosphate dehydrogenase polymorphisms and renal allograft outcome. Transplantation (2012) 0.99
Donor ABCB1 variant associates with increased risk for kidney allograft failure. J Am Soc Nephrol (2012) 0.98
Pre- and posttransplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol (2010) 0.97
Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation (2008) 0.97
Salinomycin in cancer: A new mission for an old agent. Mol Med Rep (2011) 0.97
Associations of dichlorodiphenyltrichloroethane (DDT) 4.4 and dichlorodiphenyldichloroethylene (DDE) 4.4 blood levels with plasma IL-4. Arch Environ Health (2003) 0.93
CD4+CD25+Foxp3+IFN-γ+ human induced T regulatory cells are induced by interferon-γ and suppress alloresponses nonspecifically. Hum Immunol (2011) 0.93
Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report. Hum Immunol (2009) 0.93
IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int (2012) 0.93
Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation (2007) 0.92
HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation (2009) 0.91
Observational support for an immunoregulatory role of CD3+CD4+CD25+IFN-gamma+ blood lymphocytes in kidney transplant recipients with good long-term graft outcome. Transpl Int (2008) 0.90
Interaction between dendritic cells and natural killer cells during pregnancy in mice. J Mol Med (Berl) (2008) 0.90
ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation (2012) 0.89
HLA matching and kidney transplantation: beyond graft survival. Clin Transpl (2013) 0.88
An integrative approach for the transplantation of high-risk sensitized patients. Transplantation (2010) 0.88
A new epitope-based HLA-DPB matching approach for cadaver kidney retransplants. Transplantation (2003) 0.88
Current role of human leukocyte antigen matching in kidney transplantation. Curr Opin Organ Transplant (2013) 0.88
Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology (2006) 0.87
Interferon-gamma producing regulatory T cells as a diagnostic and therapeutic tool in organ transplantation. Int Rev Immunol (2013) 0.86
Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood (2002) 0.86
CD4+ CD25+ Foxp3+ IFNγ+ CD178+ human induced Treg (iTreg) contribute to suppression of alloresponses by apoptosis of responder cells. Hum Immunol (2012) 0.86
Strong inflammatory cytokine response in male and strong anti-inflammatory response in female kidney transplant recipients with urinary tract infection. Transpl Int (2005) 0.86
Cytokine-induced killer cells targeted by the novel bispecific antibody CD19xCD5 (HD37xT5.16) efficiently lyse B-lymphoma cells. Cancer Immunol Immunother (2007) 0.86
Evaluation of T-cell receptor repertoires in patients with long-term renal allograft survival. Am J Transplant (2005) 0.86
Sequential analysis by immunoprecipitation-MALDI-TOF: a novel method for detection and identification of alloantibody specificities. Hum Immunol (2010) 0.85
Apoptosis-mediated selective killing of malignant cells by cardiac steroids: maintenance of cytotoxicity and loss of cardiac activity of chemically modified derivatives. Int Immunopharmacol (2003) 0.84
Generation of tolerogenic dendritic cells by treatment with mitomycin C: inhibition of allogeneic T-cell response is mediated by downregulation of ICAM-1, CD80, and CD86. Transplantation (2004) 0.84
HMG-CoA reductase inhibitor simvastatin overcomes bortezomib-induced apoptosis resistance by disrupting a geranylgeranyl pyrophosphate-dependent survival pathway. Biochem Biophys Res Commun (2008) 0.84
Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2. Transplantation (2013) 0.84
Risks of allogeneic hand transplantation. Microsurgery (2004) 0.84
Immunosuppressive anti-immunoglobulin autoantibodies: specificity, gene structure and function in health and disease. Cell Mol Biol (Noisy-le-grand) (2002) 0.83
Role and Value of Luminex(®)-Detected HLA Antibodies before and after Kidney Transplantation. Transfus Med Hemother (2013) 0.83
The effect of ATG on cytokine and cytotoxic T-lymphocyte gene expression in renal allograft recipients during the early post-transplant period. Clin Transplant (2003) 0.83
Increased pretransplantation plasma kynurenine levels do not protect from but predict acute kidney allograft rejection. Hum Immunol (2010) 0.83
CD4(+)CD25(+)Foxp3(+)IFNγ(+) Treg are immunosuppressive in vitro and increase with intensity of the alloresponse in pretransplant MLC. Transpl Immunol (2012) 0.83
A simplified technique for heart transplantation in rats: abdominal vessel branch-sparing and modified venotomy. Microsurgery (2006) 0.83
Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin Transplant (2009) 0.83
Expression of the heat shock cognate protein HSP73 correlates with tumour thickness of primary melanomas and is enhanced in melanoma metastases. Int J Oncol (2004) 0.83
Impact of HLA matching and HLA antibodies in organ transplantation: a collaborative transplant study view. Methods Mol Biol (2012) 0.83
Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses (2007) 0.82
Posttransplant sCD30 as a biomarker to predict kidney graft outcome. Clin Chim Acta (2011) 0.82
Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response. Transpl Int (2011) 0.82
Detection of reverse transcriptase activity in human melanoma cell lines and identification of a murine leukemia virus contaminant. Arch Dermatol Res (2005) 0.82
Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation (2015) 0.82
Suppressive dendritic cells as a tool for controlling allograft rejection in organ transplantation: promises and difficulties. Hum Immunol (2008) 0.82
Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation (2015) 0.82
A fast and simple method for detecting and quantifying donor-derived cell-free DNA in sera of solid organ transplant recipients as a biomarker for graft function. Clin Chem Lab Med (2016) 0.81
Can intravenous immunoglobulin and simvastatin solve the problem of sensitization in renal transplant candidates? Int Urol Nephrol (2007) 0.81
In-vitro inhibition of IFNγ+ iTreg mediated by monoclonal antibodies against cell surface determinants essential for iTreg function. BMC Immunol (2012) 0.81